Nifty
Sensex
:
:
23850.90
78782.24
-453.45 (-1.87%)
-606.82 (-0.76%)

Pharmaceuticals & Drugs

Rating :
N/A

BSE: 543616 | NSE: Not Listed

316
04-Nov-2024
  • Open
  • High
  • Low
  • Previous Close
  •  317.1
  •  322
  •  316
  •  323.95
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2400
  •  766260
  •  339.00
  •  136.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 363.37
  • 51.59
  • 10
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 379.64
  • N/A
  • 6.15

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 62.99%
  • 8.21%
  • 19.40%
  • FII
  • DII
  • Others
  • 6.09%
  • 0.00%
  • 3.31%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 27.03

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 24.91

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • 17.08

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Mar 24
Mar 23
Var%
Dec 23
Dec 22
Var%
Net Sales
15.45
4.60
235.87%
13.15
8.64
52.20%
0.00
8.46
-100.00%
0.00
9.41
-100.00%
Expenses
11.40
4.55
150.55%
10.66
6.88
54.94%
0.00
6.51
-100.00%
0.00
7.43
-100.00%
EBITDA
4.05
0.05
8,000.00%
2.50
1.76
42.05%
0.00
1.95
-100.00%
0.00
1.98
-100.00%
EBIDTM
26.23%
1.09%
18.99%
20.40%
0.00%
23.06%
0.00%
21.03%
Other Income
0.54
0.38
42.11%
1.15
0.33
248.48%
0.00
0.64
-100.00%
0.00
0.39
-100.00%
Interest
0.50
0.09
455.56%
0.49
0.10
390.00%
0.00
0.15
-100.00%
0.00
0.13
-100.00%
Depreciation
0.16
0.06
166.67%
0.54
0.13
315.38%
0.00
0.12
-100.00%
0.00
0.13
-100.00%
PBT
3.93
0.28
1,303.57%
2.61
1.86
40.32%
0.00
2.31
-100.00%
0.00
2.12
-100.00%
Tax
1.13
-0.34
-
1.01
0.46
119.57%
0.00
0.34
-100.00%
0.00
0.10
-100.00%
PAT
2.81
0.62
353.23%
1.60
1.40
14.29%
0.00
1.98
-100.00%
0.00
2.01
-100.00%
PATM
18.18%
13.45%
12.17%
16.22%
0.00%
23.37%
0.00%
21.41%
EPS
2.69
0.54
398.15%
1.99
1.22
63.11%
0.00
1.72
-100.00%
0.00
1.75
-100.00%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 24
Mar 23
Mar 22
Net Sales
-
44.63
31.69
21.77
Net Sales Growth
-
40.83%
45.57%
 
Cost Of Goods Sold
-
24.82
16.41
10.77
Gross Profit
-
19.81
15.29
11.00
GP Margin
-
44.39%
48.25%
50.53%
Total Expenditure
-
36.39
25.43
19.06
Power & Fuel Cost
-
0.26
0.10
0.02
% Of Sales
-
0.58%
0.32%
0.09%
Employee Cost
-
1.92
1.39
1.10
% Of Sales
-
4.30%
4.39%
5.05%
Manufacturing Exp.
-
6.26
4.64
4.63
% Of Sales
-
14.03%
14.64%
21.27%
General & Admin Exp.
-
0.91
0.71
0.81
% Of Sales
-
2.04%
2.24%
3.72%
Selling & Distn. Exp.
-
1.44
1.75
1.62
% Of Sales
-
3.23%
5.52%
7.44%
Miscellaneous Exp.
-
0.78
0.42
0.11
% Of Sales
-
1.75%
1.33%
0.51%
EBITDA
-
8.24
6.26
2.71
EBITDA Margin
-
18.46%
19.75%
12.45%
Other Income
-
2.08
1.16
0.60
Interest
-
0.65
0.48
0.13
Depreciation
-
0.97
0.36
0.20
PBT
-
8.70
6.58
2.98
Tax
-
2.76
0.56
-0.96
Tax Rate
-
31.72%
8.51%
-32.21%
PAT
-
6.34
6.02
3.95
PAT before Minority Interest
-
5.94
6.02
3.95
Minority Interest
-
0.40
0.00
0.00
PAT Margin
-
14.21%
19.00%
18.14%
PAT Growth
-
5.32%
52.41%
 
EPS
-
5.51
5.23
3.43

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Shareholder's Funds
52.90
45.63
4.78
Share Capital
11.50
11.50
8.00
Total Reserves
40.41
34.14
-3.22
Non-Current Liabilities
12.72
3.41
0.45
Secured Loans
8.81
2.75
0.00
Unsecured Loans
3.99
1.11
1.42
Long Term Provisions
0.07
0.07
0.07
Current Liabilities
20.94
11.86
7.62
Trade Payables
7.54
4.81
5.23
Other Current Liabilities
7.17
3.97
1.29
Short Term Borrowings
3.81
2.51
0.60
Short Term Provisions
2.43
0.57
0.51
Total Liabilities
87.61
62.37
12.85
Net Block
20.90
3.16
1.43
Gross Block
23.03
4.32
2.23
Accumulated Depreciation
2.14
1.16
0.80
Non Current Assets
32.99
12.18
2.10
Capital Work in Progress
4.03
4.83
0.00
Non Current Investment
3.77
3.34
0.00
Long Term Loans & Adv.
4.29
0.85
0.67
Other Non Current Assets
0.00
0.00
0.00
Current Assets
52.66
49.54
10.72
Current Investments
0.00
0.00
0.00
Inventories
12.58
7.17
3.71
Sundry Debtors
13.44
12.09
4.97
Cash & Bank
6.65
13.78
0.16
Other Current Assets
19.98
2.72
0.09
Short Term Loans & Adv.
17.84
13.78
1.79
Net Current Assets
31.72
37.68
3.10
Total Assets
87.62
62.39
12.85

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Cash From Operating Activity
2.23
-19.00
-0.21
PBT
8.70
6.58
2.98
Adjustment
0.12
0.08
0.33
Changes in Working Capital
-4.20
-25.12
-3.67
Cash after chg. in Working capital
4.61
-18.46
-0.36
Interest Paid
0.00
0.00
0.00
Tax Paid
-2.38
-0.54
0.00
Other Direct Exp. Paid
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.14
Cash From Investing Activity
-20.36
-9.69
-0.45
Net Fixed Assets
-9.08
-2.27
Net Investments
-0.36
-3.99
Others
-10.92
-3.43
Cash from Financing Activity
11.01
42.28
0.80
Net Cash Inflow / Outflow
-7.13
13.60
0.14
Opening Cash & Equivalents
13.78
0.18
0.01
Closing Cash & Equivalent
6.65
13.78
0.16

Financial Ratios

Standalone /

Consolidated
Description
Mar 24
Mar 23
Mar 22
Book Value (Rs.)
43.43
39.11
5.93
ROA
7.92%
16.00%
30.72%
ROE
12.52%
24.21%
83.23%
ROCE
15.32%
23.60%
43.21%
Fixed Asset Turnover
3.26
9.68
9.76
Receivable days
104.41
98.21
83.27
Inventory Days
80.77
62.65
62.24
Payable days
90.79
111.70
177.25
Cash Conversion Cycle
94.40
49.17
-31.74
Total Debt/Equity
0.37
0.17
0.52
Interest Cover
14.42
14.67
24.72

Annual Reports:

News Update:


  • Trident Lifeline - Quarterly Results
    19th Oct 2024, 18:01 PM

    Read More
  • Trident Lifeline commences commercial production at manufacturing plant in Surat
    13th Sep 2024, 09:39 AM

    The New Manufacturing unit installed with manufacturing capacity of 50,000 Syrup Bottle and 50,000 Ointments per day

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.